Essential Hypertension (Adjunctive)
Investigational adjunctive use with only non-randomized clinical reports identified; proposed mechanisms are blood-volume removal and hirudin effects on vessels; not a substitute for pharmacotherapy.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for high blood pressure is investigational.
- What evidence exists?
- Tier C (investigational). Reports of lower blood pressure after leech application come from clinical series and non-randomized comparisons, mostly Russian; no randomized controlled trial was identified. Evidence-based first-line therapy is lifestyle change (sodium reduction, weight loss, exercise, alcohol moderation) plus proven antihypertensive medications (thiazides, ACE inhibitors / ARBs, calcium channel blockers) — these have decades of cardiovascular-outcome data behind them.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the placement areas for 5 to 10 days
- Lightheadedness or low blood pressure on standing, especially if antihypertensive medications are not adjusted
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Anemia from cumulative blood loss across multiple sessions
- False reassurance leading to skipping or delaying evidence-based pharmacotherapy — with risk of heart attack, stroke, kidney disease
- Who should not consider this
- Patients with severe uncontrolled hypertension (BP over 180/110)
- Patients within 6 months of a heart attack, stroke, or transient ischemic attack
- Patients with symptomatic orthostatic hypotension or frequent falls
- Patients on anticoagulants (warfarin, DOACs, heparin)
- Patients with hemophilia, anemia, or active infection
- Patients using this as a replacement for prescribed antihypertensives
- What to ask your clinician
- What is my cardiovascular risk score, and what is my blood-pressure target?
- Have I tried lifestyle modification (DASH diet, sodium under 1500 mg/day, regular aerobic exercise, weight loss if applicable)?
- What antihypertensive medications have I tried, and at what doses?
- Will my prescriber be involved in dose adjustment if I pursue complementary therapy?
- How will my blood pressure be monitored during and after treatment (home BP log)?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the realistic effect size and duration?
- When to seek urgent care
- Chest pain, pressure, or shortness of breath (possible heart attack — call 911)
- Sudden weakness on one side, slurred speech, facial droop, or vision loss (possible stroke — call 911)
- Blood pressure over 180/120 with headache, vision change, or chest pain (hypertensive emergency)
- Severe lightheadedness, fainting, or a fall
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F, spreading redness, or pus
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for hypertension.
- Small short-term BP reductions in case series do NOT prove reduction of heart attack, stroke, or kidney damage.
- Mechanism rationale (volume reduction, endothelial effects) does NOT establish clinical efficacy at scale.
- Leech therapy is NEVER a substitute for evidence-based antihypertensive medications when indicated.
- Any antihypertensive medication changes require your prescriber's involvement, not self-titration.
Safety cross-references
Clinical Profile
- Category
- Cardiovascular
- ICD-10
- I10
- Safety tier
- Medium
Evidence Summary
Historical use of bloodletting for hypertension dates to antiquity. No randomized controlled trial of leech therapy for essential or resistant hypertension was identified. The human evidence consists of small, mostly Russian-language, uncontrolled or non-randomized clinical series described in the 2004 monograph of Baskova and Isakhanyan (for example Zadorova 1998, 83 patients, systolic pressure down by about 10-20 mmHg on average; a 2003 conference study by Sidorov and colleagues, 100 patients versus 41 controls, with pressure falling in 61.9% and transiently rising in 28.6%) and in two journal reports: Isakhanian and Arutiunian 1991 (Ter Arkh) and Chufarovskaya 2011 (10 women with grade 1-2 hypertension, 146.5/93.5 to 122.8/81.4 mmHg while antihypertensive doses were being reduced). The monograph itself notes small samples, missing control groups and no statistical analysis in several of these studies. Any use is investigational. The proposed mechanism combines a temporary blood-volume reduction (analogous to therapeutic phlebotomy in polycythemia) with hypothesized endothelial effects from absorbed salivary peptides, but neither has been shown in a randomized controlled trial to lower blood pressure in patients. ASH position: leech therapy is NEVER a replacement for evidence-based antihypertensive pharmacotherapy and should not be used as a substitute for it. It has no established role in the management of hypertension and should only be considered, if at all, within a research protocol under cardiology supervision.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan include essential hypertension (hypertensive disease) and symptomatic arterial hypertension in the list of conditions for which, in their words, treatment with leeches is recommended; in their own series of 42 patients with raised blood pressure (23 with essential hypertension, 19 with symptomatic hypertension), described without a comparison group, they considered the treatment effective in 31 patients, but at the same time they note that in an individual patient leeches do not lower blood pressure but only help to reduce the number and “coloring” of complaints (as stated in the book)[B1].
- Baskova and Isakhanyan retell reports from a 2003 conference: according to them, patients with essential hypertension often showed a slight or moderate rise in blood pressure after leeches, and Maksyutkina and Chekulaeva concluded that patients with high blood pressure who are prone to hypertensive crises may, in their words, suffer severe vascular complications after leeches, and that hypertension with high readings and a crisis course is a relative contraindication to hirudotherapy[B1].
- Baskova and Isakhanyan themselves point out that in the clinical studies by Maksyutkina, Chekulaeva, Smirnova, Petrova and Yakovleva the sample is small, there are no control groups, only blood pressure was measured, the material was not processed statistically and the cause of the hypertension was not classified, and that all this, in their words, casts doubt on these authors’ conclusions[B1].
- In the studies that Baskova and Isakhanyan retell (Ena, 1998; Gantimurova et al., 2001), leeches were used together with blood pressure medicines; in the study by Gantimurova et al. the control group received only medicines[B1].
- Michalsen et al. write that in the past leech therapy was commonly used for arterial hypertension, but modern treatment regimens include a great number of reliable drugs and lifestyle changes, so hirudotherapy is now largely seen as a welcome adjuvant therapy rather than as a first-line treatment; the application of leeches to specific areas of the body (the neck region and others) they note as described, but study data on this, in their words, are not available[B3].
- In the chapter on safety, Michalsen describes two outpatients with known arterial hypertension who were taking three blood pressure–lowering drugs and continued taking them as usual: in both, blood pressure fell after leeches and a few hours later there was a brief, benign fainting attack, and the author reminds readers that leeches themselves lower blood pressure[B3].
- Among contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure, acute vascular insufficiency (shock, collapse, fainting) and concurrent use of anticoagulants, while Flecken and Michalsen call the use of anticoagulants (Marcumar, warfarin, heparin, heparinoids) an absolute contraindication and write that treatment involving blood removal is generally contraindicated in anemia[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Uncontrolled severe hypertension (BP >180/110)
- Recent (<6 months) myocardial infarction or stroke
- Symptomatic orthostatic hypotension
Related ASH Compounds
Leech molecules and hirudin-derived drugs mentioned for this condition, each profiled in the ASH compound registry:
Related Conditions
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.
Atrial Fibrillation (Adjunctive Investigational)
Highly investigational adjunct for paroxysmal atrial fibrillation; no controlled trials; conventional anticoagulation and rate/rhythm control remain primary.
Congestive Heart Failure (Compensated, Investigational Adjunct)
Investigational adjunct in compensated NYHA II heart failure; only small open-label or uncontrolled studies were identified, mostly in Russian-language sources; guideline-directed medical therapy remains primary.
Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.